PZRXQ (PhaseRx) EBITDA Margin %: 0.00% (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx EBITDA Margin %?

PhaseRx PZRXQ -99.00% EBITDA Margin % is 0.00% as of Sep. 2017.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PhaseRx's EBITDA for the three months ended in Sep. 2017 was $-2.50 Mil. PhaseRx's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, PhaseRx's EBITDA margin for the quarter that ended in Sep. 2017 was 0.00%.

PhaseRx  (OTCPK:PZRXQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

PhaseRx EBITDA Margin % Related Terms

PhaseRx EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for PhaseRx's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx EBITDA Margin % Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
EBITDA Margin %
-414.17 -1,439.20 0.00

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PZRXQ vs NSPX, HSTC, PRGBQ: EBITDA Margin % Comparison

For the Biotechnology subindustry, PhaseRx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseRx EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PhaseRx's EBITDA Margin % falls into.


PhaseRx EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PhaseRx's EBITDA Margin % for the fiscal year that ended in Dec. 2016 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2016 )/Revenue (A: Dec. 2016 )
=-17.943/0
= %

PhaseRx's EBITDA Margin % for the quarter that ended in Sep. 2017 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2017 )/Revenue (Q: Sep. 2017 )
=-2.499/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
PhaseRx (PZRXQ) has a EBITDA Margin % of 0.00% as of Sep. 2017. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PhaseRx and its competitors.
Is PhaseRx's EBITDA Margin % too high?
PhaseRx's current EBITDA Margin % is 0.00%.
How does PhaseRx's EBITDA Margin % compare to NSPX and HSTC?
PhaseRx's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PhaseRx and its competitors. PhaseRx's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current EBITDA Margin % is 0.00% as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.